Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

被引：8
|
作者：
Patel, J. D.
Hensing, T. A.
Rademaker, F.
Hart, E.
Obasaju, C. K.
Treat, J.
Milton, D.
Bonomi, P. D.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Evanston Northwestern Healthcare, Evanston, IL USA
[3] Lilly Oncol, Indianapolis, IN USA
[4] St Vincents Hosp, Indianapolis, IN USA
[5] Rush Univ, Med Ctr, Chicago, IL 60612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8044
引用
收藏
页数：1
相关论文
共 50 条
  • [41] FEASIBILITY STUDY OF PEMETREXED (PEM) PLUS BEVACIZUMAB (BV) AS THE FIRST-LINE TREATMENT FOR ELDERLY ADVANCED OR RECURRENT NON-SQUAMOUS (NON-SQ) NON-SMALL CELL LUNG CANCER (NSCLC): TORG1015.
    Kozuki, Toshiyuki
    Nogami, Naoyuki
    Kitajima, Hiromoto
    Shinkai, Tetsu
    Kato, Fumiaki
    Sakaida, Emiko
    Takiguchi, Yuichi
    Ikeda, Satoshi
    Yoshida, Masahiro
    Enomoto, Yasunori
    Kato, Terufumi
    Ogura, Takashi
    Miyamato, Shingo
    Morita, Satoshi
    Watanabe, Koshiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S870 - S870
  • [42] First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China
    Chang, Qing
    Zhang, Yanwei
    Xu, Jianlin
    Zhong, Runbo
    Qiang, Huiping
    Zhang, Bo
    Han, Baohui
    Qian, Jialin
    Chu, Tianqing
    THORACIC CANCER, 2019, 10 (05) : 1043 - 1050
  • [43] PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Megaiz, Ahlem
    Bousahba, Abdelkader
    Rabah, Aicha
    Zemmour, Amel
    Ahed-Messaoud, Malika
    Ghazli, Soumia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S588 - S589
  • [44] A retrospective study of maintenance pemetrexed in advanced non-squamous non-small cell lung cancer
    Oguh, L.
    Ranatunge, D.
    Lind, M.
    Ukadhyay, S.
    El-Mahdawi, N.
    LUNG CANCER, 2018, 115 : S30 - S30
  • [45] A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC)
    Krupitskaya, Y.
    Ganjoo, K.
    Lavori, P. W.
    Kumar, A.
    Clement-Duchene, C.
    Zhao, G.
    Padda, S.
    San Pedro-Salcedo, M.
    Wakelee, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] 65 plus: A randomized phase III trial of Pemetrexed and Bevacizumab vs. Pemetrexed, Bevacizumab and Carboplatin as 1st line treatment for elderly patients with advanced non-squamous, non-small cell lung cancer (NSCLC) - a subgroup analysis of age and gender
    Schuette, W.
    Nieman, B.
    Schneider, C. P.
    Engel-Riedel, W.
    Schumann, C.
    Kohlhaeufl, M.
    Serke, M.
    Hoeffken, G.
    Kortsik, C.
    Reck, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S623 - S623
  • [47] An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer
    Nuijten, Mark J. C.
    Aultman, Rick
    de Castro Carpeno, Javier
    Vergnenegre, Alain
    Chouaid, Christos
    Walzer, Stefan
    Siebert, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2193 - 2201
  • [48] Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC).
    Graham, Christopher N.
    Knox, Hediyyih N.
    Winfree, Katherine B.
    Hess, Lisa M.
    Liu, Jingyi
    Ortuzar, Waldo Feliu
    Zinner, Ralph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)
  • [49] Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
    Okamoto, Isamu
    Schuette, Wolfgang H. W.
    Stinchcombe, Thomas E.
    Rodrigues-Pereira, Jose
    San Antonio, Belan
    Chen, Jian
    Liu, Jingyi
    John, William J.
    Zinner, Ralph G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (05) : 937 - 941
  • [50] First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)
    Spigel, David R.
    Mekhail, Tarek M.
    Waterhouse, David
    Hadley, Terence
    Webb, Charles
    Burris, Howard A.
    Hainsworth, John D.
    Greco, F. Anthony
    CANCER INVESTIGATION, 2017, 35 (08) : 541 - 546
12345